Aberdeen Group
CORT icon

Aberdeen Group’s Corcept Therapeutics CORT Stock Holding History

Aberdeen Group’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-245,093
Closed -$8.53M – 945
2025
Q4 		$8.53M Sell
245,093
-13,984
-5% -$1.1M 0.01% 633
2025
Q3 		$21.5M Sell
259,077
-19,501
-7% -$1.41M 0.03% 407
2025
Q2 		$20.4M Sell
278,578
-29,976
-10% -$2.17M 0.03% 405
2025
Q1 		$35.2M Sell
308,554
-127,341
-29% -$7.75M 0.07% 246
2024
Q4 		$22M Sell
435,895
-231,057
-35% -$12.1M 0.04% 347
2024
Q3 		$30.9M Buy
666,952
+142,310
+27% +$5.06M 0.06% 294
2024
Q2 		$17M Buy
+524,642
New +$14.4M 0.03% 416

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Aberdeen Group's CORT Position: Q1 2026 in Review

Aberdeen Group sold out of Corcept Therapeutics (CORT) in Q1 2026, closing a stake of 245,093 shares — an estimated $8.53M sold.

Aberdeen Group first reported a position in CORT in Q2 2024 and held it in 7 quarters. The position peaked at $35.2M in Q1 2025. 352 funds tracked by Wall St. Rank hold CORT as of Q1 2026.

  • Aberdeen Group reported no remaining Corcept Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Aberdeen Group sold 245,093 Corcept Therapeutics shares in Q1 2026, an estimated $8.53M.
  • Aberdeen Group first reported a position in Corcept Therapeutics in Q2 2024 and held it in 7 quarters.
  • Aberdeen Group's Corcept Therapeutics position peaked at $35.2M in Q1 2025.
  • 352 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2026.

Based on Aberdeen Group's 13F filing for Q1 2026, filed 29 Apr 2026.